Trivarx Limited · ASX:TRI
Trivarx — Shareholder Meeting (November 2020)
16 slides from Trivarx's shareholder meeting presentation, Nov 12, 2020
Slide 1: 2020 AGM Presentation
2020 AGM PRESENTATION ASX: MEB OTCPINK: MDBIF NOV 2020 © Medibio Limited 2016
Slide 2: Forward Looking Statements
FORWARD LOOKING STATEMENTS FORWARD LOOKING The purpose of the presentation is to provide an update of the business of Medibio Limited (ASX:MEB) (OTCPINK: STATEMENTS MDBIF). These slides have been prepared as a presentation aid only and the information they contain may require further explanation and
Slide 3: Looking at Mental Health Objectively
LOOKING AT MENTAL HEALTH OBJECTIVELY A mental health technology company pioneering the use of objective measures to aid in the early detection and screening of mental health conditions. Pione e ring the use of obje ctive me asure s with artificial Inte llige nce and ne ural ne twork me thodology to
Slide 4: We will no longer endorse DSM5, as it has fundamental flaws
“We will no longer endorse DSM5, as it has fundamental flaws and we are actively seeking a diagnostic system that is evidence based. We need a quantitative method for diagnosing depression” - National Institute of Mental Health in the USA, 2013 © 2020 Medibio Limited 10
Slide 5: Depressive Burden Trial (SADB) to Validate MEB-001
DEPRESSIVE BURDEN TRIAL (SADB) TO VALIDATE MEB - 001 MEB-001 is a software medical device that Our team in Minneapolis is currently undertaking a clinical trial known as the consists of 3 main components: “Sleep Analysis of Depressive Burden” The sleep staging 1 algorithms; overlaid by The purpose o
Slide 6: Breakthrough Device Designation for MEB-001
BREAKTHROUGH DEVICE DESIGNATION- FOR MEB - 001 To qualify for Breakthrough Device Designation we must establish that MEB -001 promises a more effective diagnosis of a life-threatening or irreversibly debilitating condition; and meet at least one of the following criteria: a) That MEB-001 represents
Slide 7: MEBsleep
MEBsleep MEBsleep uses artificial intelligence, deep learning algorithms and neural network methodology to identify the five important sleep stages of a patient. The primary purpose of MEBsleep is the identification of sleep stages, which is an essential part of MEB -001. MEBsleep is able to It is t
Slide 8: MEB-001 / MEBsleep Revenue Model
MEB-001 / MEBsleep REVENUE MODEL Medibio will earn revenue based on the number of depressive burden and/or sleep staging reports produced © 2020 Medibio Limited
Slide 9: Clinical Trial Agreement with MedBridge Healthcare LLC in the USA
CLINICAL TRIAL AGREEMENT WITH MEDBRIDGE HEALTHCARE LLC IN THE USA As we have previously reported, the closure of sleep clinics in Minneapolis due to the COVID-19 lockdown put a sudden stop to our depressive burden trial for a period of approximately 3 months. In order to make up for lost time, on 24
Slide 10: Benefits of ilumen
BENEFITS of ILUMEN FOR EMPLOYERS Provides employers with a real-time, de- identified, aggregated dashboard of their workforce’s results to better support and manage the mental well-being of its workforce and measure the impact of their programs FOR EMPLOYEES Provides employees an early screening too
Slide 11: Compass Group PLC
COMPASS GROUP PLC GLOBAL (600,000 employees, 45 countries) OFFSHORE BUSINESS & DEFENSE EDUCATION HEALTHCARE & REMOTE INDUSTRY © 2020 Medibio Limited
Slide 12: Mr Federico Tonetti, Global Safety & Sustainability Director at Compass
Mr Federico Tonetti, Global Safety & Sustainability Director at Compass in London. “When dealing with mental health, the biggest challenge as an employer is moving the emphasis from the input of what we do, to measuring the output. There are many campaigns around mental health. Many countries have m
Slide 13: Licence Fees
REVENUE MODEL- SasS MODEL, ENTERPRISE LICENSE ($ Per Employee, Per Annum) LICENCE FEES COMPASS GROUP COMPANIES AND / OR Compass Clients © 2020 Medibio Limited
Slide 14: Consumer App Trigger Analysis
CONSUMER APP Trigger Disruptive event Goal refinement Analysis Intention Biometrics Self Expectation Self Reflection Goal Setting Goal outcomes Exercises © 2020 Medibio Limited
Slide 15: Looking Forward / 2020-2021
LOOKING FORWARD/ 2020 -2021 We look forward with a great deal of confidence to achieving a number of significant milestones. Securing the first Securing 510(k) clearance Securing of many Compass additional ilumen for MEBsleep Breakthrough Companies and licenses in paving the way for Device Designati
Slide 16: Claude Solitario, Managing Director
CLAUDE SOLITARIO Managing Director Melbourne Level 4, 100 Albert Road South Melbourne VIC 3205 United States HQ 8696 Eagle Creek Circle Savage, MN 55378